263 related articles for article (PubMed ID: 26983806)
21. Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
Elis W; Triantafellow E; Wolters NM; Sian KR; Caponigro G; Borawski J; Gaither LA; Murphy LO; Finan PM; Mackeigan JP
Mol Cancer Res; 2008 Apr; 6(4):614-23. PubMed ID: 18403640
[TBL] [Abstract][Full Text] [Related]
22. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
Kuo PL; Chen YH; Chen TC; Shen KH; Hsu YL
J Cell Physiol; 2011 May; 226(5):1224-31. PubMed ID: 20945384
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus.
Banfic H; Visnjic D; Mise N; Balakrishnan S; Deplano S; Korchev YE; Domin J
Biochem J; 2009 Jul; 422(1):53-60. PubMed ID: 19496756
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways.
Choi SC; Kim SJ; Choi JH; Park CY; Shim WJ; Lim DS
Stem Cells Dev; 2008 Aug; 17(4):725-36. PubMed ID: 18788932
[TBL] [Abstract][Full Text] [Related]
25. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways.
Qiu Q; Yang M; Tsang BK; Gruslin A
Reproduction; 2004 Sep; 128(3):355-63. PubMed ID: 15333786
[TBL] [Abstract][Full Text] [Related]
26. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
27. PI3K signalling in inflammation.
Hawkins PT; Stephens LR
Biochim Biophys Acta; 2015 Jun; 1851(6):882-97. PubMed ID: 25514767
[TBL] [Abstract][Full Text] [Related]
28. Effect of inhibitors of mitogen-activated protein kinase kinase on alpha(1B)-adrenoceptor phosphorylation.
Alcántara-Hernández R; Adolfo García-Sáinz J
Auton Autacoid Pharmacol; 2009 Jan; 29(1-2):13-23. PubMed ID: 19302552
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia enhances FGF2- and VEGF-stimulated human placental artery endothelial cell proliferation: roles of MEK1/2/ERK1/2 and PI3K/AKT1 pathways.
Wang K; Jiang YZ; Chen DB; Zheng J
Placenta; 2009 Dec; 30(12):1045-51. PubMed ID: 19892399
[TBL] [Abstract][Full Text] [Related]
30. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
31. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.
Arcaro A; Zvelebil MJ; Wallasch C; Ullrich A; Waterfield MD; Domin J
Mol Cell Biol; 2000 Jun; 20(11):3817-30. PubMed ID: 10805725
[TBL] [Abstract][Full Text] [Related]
32. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells.
Liu S; Gao F; Wen L; Ouyang M; Wang Y; Wang Q; Luo L; Jian Z
Cell Physiol Biochem; 2017; 43(3):1100-1112. PubMed ID: 28977794
[TBL] [Abstract][Full Text] [Related]
33. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
34. Evidence from bioinformatics, expression and inhibition studies of phosphoinositide-3 kinase signalling in Giardia intestinalis.
Cox SS; van der Giezen M; Tarr SJ; Crompton MR; Tovar J
BMC Microbiol; 2006 May; 6():45. PubMed ID: 16707026
[TBL] [Abstract][Full Text] [Related]
35. Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin.
Miyata Y; Sato T; Yano M; Ito A
Mol Cancer Ther; 2004 Jul; 3(7):839-47. PubMed ID: 15252145
[TBL] [Abstract][Full Text] [Related]
36. An Overview of Class II Phosphoinositide 3-Kinases.
Heng EYZ; Maffucci T
Curr Top Microbiol Immunol; 2022; 436():51-68. PubMed ID: 36243839
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.
Hagemeister AL; Sheridan MA
Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R490-7. PubMed ID: 18495839
[TBL] [Abstract][Full Text] [Related]
38. Carvacrol Alleviates Prostate Cancer Cell Proliferation, Migration, and Invasion through Regulation of PI3K/Akt and MAPK Signaling Pathways.
Luo Y; Wu JY; Lu MH; Shi Z; Na N; Di JM
Oxid Med Cell Longev; 2016; 2016():1469693. PubMed ID: 27803760
[TBL] [Abstract][Full Text] [Related]
39. Essential role of class II phosphatidylinositol-3-kinase-C2α in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells.
Biswas K; Yoshioka K; Asanuma K; Okamoto Y; Takuwa N; Sasaki T; Takuwa Y
J Biol Chem; 2013 Jan; 288(4):2325-39. PubMed ID: 23192342
[TBL] [Abstract][Full Text] [Related]
40. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
